Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 7/7/2015 11:13:37 PM - Followers: 679 - Board type: Free - Posts Today: 0

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

Apr 21, 2015
Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


                                             ELTP Potential Share Price in Relation to Percentage of Pain Market Captured

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 06/22/2015 02:47:10 PM
ELTP News: Annual Report (10-k) 06/15/2015 04:36:59 PM
ELTP News: Undervalued and Underexposed NYSE-MKT Stock to be Profiled by Large Media Group and four brief reports 06/15/2015 07:00:00 AM
ELTP News: Current Report Filing (8-k) 06/09/2015 01:41:17 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 06/04/2015 04:08:55 PM
#156597  Sticky Note A few more additional FACTS about the Actavis/Epic/Elite Couch 06/11/15 08:13:37 PM
#156525  Sticky Note Elite^Epic Power Partnership! I believe this partnership is Brilliant! As Bngo 06/11/15 02:08:37 PM
#156231  Sticky Note FOR THOSE WANTING A DEEPER UNDERSTANDING OF WHY Couch 06/09/15 08:10:52 PM
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#142585  Sticky Note Great info! This is the beginning of a Dr Speculator Ninja 01/29/15 02:56:03 PM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#159221   perfect storm.... PERFECT BAD STORM BREWING SCHH 07/07/15 11:13:37 PM
#159220   Another example of what I have been saying IB_ 07/07/15 10:05:13 PM
#159219   mT Keeping it real: snupoled 07/07/15 08:30:57 PM
#159218   A.T.f.guy, your catching the eltp spirit, pass it along man! snupoled 07/07/15 08:24:43 PM
#159217   ELTP trading done right. John_Langston 07/07/15 07:38:39 PM
#159216   Gman24, Dr PeteRose MLB 07/07/15 07:31:03 PM
#159215   Ryan: Make Opioids Harder To Abuse Couch 07/07/15 07:02:37 PM
#159214   That was some nice ELTP ask slapping at John_Langston 07/07/15 06:24:38 PM
#159213   ELTP 3 mos price chart and 6 mos sharpei 07/07/15 05:05:08 PM
#159210   Certainly not embarrassed to take a full salary mrwrn2010 07/07/15 02:31:32 PM
#159209   Since CEO signed up a few years ago NASDAQ2020 07/07/15 02:27:32 PM
#159208   As a True Elite Long I find the IB_ 07/07/15 02:23:49 PM
#159207   More misinformation. Face it Nasrat said he wouodn't Couch 07/07/15 02:11:30 PM
#159206   On the contrary, there is not enough ammo Aqua 07/07/15 02:04:32 PM
#159205   I heard the same misinformation at .06 cents. Couch 07/07/15 01:33:22 PM
#159203   Elite up 300% since Nasrat signed on a NASDAQ2020 07/07/15 01:18:35 PM
#159202   Some of us are rich enough from flipping NASDAQ2020 07/07/15 01:15:13 PM
#159200  Restored Yeah, but I think he was one of dr_lowenstein 07/07/15 01:03:20 PM
#159199   Snup- Once the FDA gives the go ahead mts 07/07/15 12:58:49 PM
#159198   Maybe because Elite is not as good as Money_Tree 07/07/15 12:52:00 PM
#159197   If you add them up, we get a Aqua 07/07/15 12:44:03 PM
#159195   Taking a long-term, value investing approach is not Aqua 07/07/15 12:10:05 PM
#159194  Restored Some of us are rich enough from flipping richme 07/07/15 12:06:14 PM
#159193   Explain how todays action with Eltp sucks. I utamaro71 07/07/15 11:30:36 AM
#159192   Mts, at least they have HYPE, WHERE/WHEN IS ELITES? snupoled 07/07/15 11:19:18 AM
#159191   Investors are not accepting the hype on Embeda mts 07/07/15 10:49:54 AM
#159190  Restored What is it that the ancients used to no2koolaid 07/07/15 10:48:12 AM
#159189   This link from Seeking Alpha says what I no2koolaid 07/07/15 10:37:36 AM
#159188   Another voice calling for opioid addiction help: tempaussie 07/07/15 10:07:49 AM
#159187   Agree. Investors are not accepting NH's hype and richme 07/07/15 10:06:40 AM
#159186   James, I agree it is atypical for a penny snupoled 07/07/15 09:31:12 AM
#159185   Elite better hurry if they are gonna make IB_ 07/07/15 09:29:38 AM
#159184   trivia ? snupoled 07/07/15 09:25:25 AM
#159183   Thanks clare, ..., lets see if it's got legs sharkey1 07/07/15 08:38:35 AM
#159182   Isradipine Hypertension drug isradipine may stop drug and alcohol addiction: Clarendon 07/07/15 08:11:50 AM
#159181   Logically, no; however, the stock market, including the Aqua 07/06/15 11:59:39 PM
#159180   In short, the Greeks reaped what they had Aqua 07/06/15 11:41:51 PM
#159179   I believe you have mistaken Elite's CEO for no2koolaid 07/06/15 11:32:34 PM
#159178   Yep. Not one bit of sympathy for socialist for real 07/06/15 11:29:15 PM
#159177   Sorry, but the plain fact is that global no2koolaid 07/06/15 11:27:26 PM
#159176   The Greek debt crisis is misunderstood by all no2koolaid 07/06/15 11:21:38 PM
#159175   Well, ELTP will have no problems attracting short-term Aqua 07/06/15 11:20:57 PM
#159174   Exactly- lock your shares up now and upon Couch 07/06/15 10:36:43 PM
#159173   I meant: Expect to Elite to play Aqua 07/06/15 10:36:24 PM
#159172   Always cracks me up when people talk about mrwrn2010 07/06/15 09:52:43 PM
#159171   Once you start loaning credit to a bunch Aqua 07/06/15 09:25:36 PM
#159170   What's for sure, Nasrat wants more NASDAQ2020 07/06/15 08:52:30 PM
#159169   Lol. Ya me too. for real 07/06/15 08:50:05 PM
#159168   More misinformation. Nasrat hasn't sold one single solitary share. Couch 07/06/15 08:47:01 PM
#159167   Yes the FDA must've bought the Elite hype Couch 07/06/15 08:35:35 PM